Le Lézard
Classified in: Health, Science and technology

Oxford Nanopore Announces Technology Updates


OXFORD, UK / ACCESSWIRE / December 2, 2021 / Highlights include release of new "Kit 12" and R10.4 flow cells for >Q20 (>99%) raw read and around Q30 (99.9%) Duplex sequencing accuracy, and the new PromethION P2 device, a palm-sized, high-throughput sequencer that delivers the most accessible low-cost, high-output Oxford Nanopore sequencer

Oxford, UK: Oxford Nanopore has provided a technology update at its Nanopore Community Meeting, describing a range of product releases and upgrades. These include the release of "Kit 12", a new kit that includes the latest "Q20+" chemistry and enables "Duplex" sequencing. This is coupled with the release of R10.4 flow cells. Users of nanopore sequencing can now achieve >Q20 raw read/"simplex" accuracy or around Q30 Duplex accuracy, and enhanced, high-accuracy consensus sequencing and variant calling, using these released products.

The Company has also announced PromethION 2 (P2), a device that can run up to two high-throughput PromethION Flow Cells, which will be available in starter packs from US$10,455. The P2 is designed to bring low-cost nanopore sequencing for large genomes or high-throughput long-read transcriptomics, without the requirement for capital investment and with minimal infrastructure requirement. P2 will be available as a standalone device with integrated compute, or "P2 Solo", a sequencing device that can be connected to existing compute, including GridION. P2 Solo will be shipped from Q2 2022 and Oxford Nanopore is now taking pre orders here. ?

Oxford Nanopore also introduced Remora, a new tool for methylation analysis. Remora further enhances base-modification analysis, and is used during the experiment (concurrent to standard basecalling), at no additional cost, while maintaining high-accuracy basecalling of native bases. Remora provides industry-leading performance at only 20X coverage.

"Short fragment mode" (SFM), to optimise accurate, high-throughput sequencing of shorter fragments as short as 20 bp, will be fully enabled in the new year.? Oxford Nanopore's technology sequences DNA or RNA molecules of any length, from short to ultra-long. However, software output settings have historically avoided shorter "adapter only" reads. SFM is designed to optimise applications where larger volumes of shorter fragments require high-accuracy analysis, supporting as many as 250M native human reads, at ~200 bp, on a PromethION flow cell.

"Path to in-field liquid biopsy". R&D pipeline programmes were reviewed, including chemistries such as "inny" and "outy", that capture a single molecule of DNA and make multiple measurements of that single molecule. These techniques have the potential to deliver "Adaptive Accuracy" - supporting capture and re-reading of rare variants in a mixed sample.? could be paired with liquid biopsy workflows in the lab or in the field, potentially enabling easy-to-use remote "liquid biopsy" sequencing.

The Company is developing an integrated sequencer and tablet; the MinION Mk1D, that would be capable of processing the high data volumes produced by MinION and could be used for this purpose.

Nanopore Community Meeting

The annual Nanopore Community Meeting, held online in 2021, has this year featured more than 50 user talks, spanning areas including human genetics, clinical / cancer research, microbiology including genomic epidemiology, plant and animal research and bioinformatics.? Write ups and videos of the talks are made available on the nanopore website.? At the meeting, Oxford Nanopore provided a technology update, featuring Clive G Brown (CTO) and talks from James Clarke, Stuart Reid and Rosemary Sinclair Dokos.?

For a complete overview of these and more announcements, please visit Oxford Nanopore's website at https://nanoporetech.com/about-us/news/oxford-nanopore-announces-technology-updates-nanopore-community-meeting

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Oxford Nanopore Technologies plc



View source version on accesswire.com:
https://www.accesswire.com/675688/Oxford-Nanopore-Announces-Technology-Updates


These press releases may also interest you

at 17:13
The Center for Health Affairs is happy to announce the appointment of two new members to its Community Health Affairs Board of Directors. In addition, Susan Fuehrer, president of The MetroHealth System's Institute for H.O.P.E., has been named chair,...

at 17:13
Cate Osborn never dreamed before COVID hit that she'd be the creator of a thriving social media community of more than 2 million in just one year. Known as @catieosaurus online, Cate, who is a mental health advocate, full-time content creator, and...

at 17:00
Vaccination against COVID-19 did not affect fertility outcomes in patients undergoing in-vitro fertilization (IVF), a new study has found. The findings, which were published in Obstetrics & Gynecology (the Green Journal), add to the growing body of...

at 17:00
Endo International plc will announce its fourth?quarter and full-year 2021 financial results on February 28, 2022 and members of its senior management team will host a conference call and webcast on March 1, 2022 at 7:30am ET before the U.S....

at 16:35
Incyte today announced updates regarding the clinical development of parsaclisib, the Company's next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3K?), and MCLA-145, its CD137/PD-L1 bispecific antibody co-developed under a...

at 16:15
The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share, payable on March 31, 2022 to holders of record on March 10, 2022. The indicated annual dividend rate is $3.48 per share. ...



News published on 2 december 2021 at 02:00 and distributed by: